Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-181 long-term safety in chronic pain
NCT02367820Phase 3Completed
- Sponsor
- Nektar Therapeutics
- Start
- Apr 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of oxycodone in chronic low back pain (CLBP) and Chronic non-cancer pain (CNCP), sponsored by Nektar Therapeutics. Primary endpoint: Number of Participants Reporting Adverse Events at 57 weeks. Started Apr 2015; status: completed.
02
Drugs
oxycodone
03
Conditions
chronic low back pain (CLBP)Chronic non-cancer pain (CNCP)
Beyond the preview
Go deeper on NCT02367820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367820.